Second-line everolimus treatment is effective in RCC patients with poor progression-free survival (PFS) in first-line VEGF-targeted therapies.
V. Gruenwald
Consultant or Advisory Role - GlaxoSmithKline; Novartis; Pfizer; Roche
Honoraria - GlaxoSmithKline; Novartis; Pfizer; Roche
C. Seidel
No relevant relationships to disclose
J. Busch
No relevant relationships to disclose
M. Fenner
No relevant relationships to disclose
S. Weikert
No relevant relationships to disclose